News >

Expert Tracks the Activity of PARP Inhibitors in Ovarian Cancer

Caroline Seymour
Published: Wednesday, Jul 11, 2018

Dr NAME – no MD

Gottfried E. Konecny, MD

Three international studies have shown the value of PARP inhibition after achieving a complete or partial response to chemotherapy for patients with ovarian cancer, with the greatest benefit in those who harbor germline or somatic BRCA mutations, said Gottfried E. Konecny, MD.

State of the Science Summit™ on Ovarian Cancer, Konecny, an associate professor of medicine, University of California, Los Angeles, discussed developments in the understanding of response to PARP inhibition in ovarian cancer.

OncLive: What are the updates in PARP inhibition in ovarian cancer?

Konecny: We now understand that about 50% percent of all patients with ovarian cancer harbor a deficiency in DNA damage repair. This makes them susceptible to DNA-damaging agents, such as platinum agents or PARP inhibitors. We now have 3 PARP inhibitors approved for the treatment of patients with ovarian cancer. The first experience we had with these inhibitors was in patients with recurrent disease, specifically with germline BRCA and later somatic mutations.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: ASCO Direct™ Highlights – 2019 Official Annual Meeting ReviewAug 30, 20201.5
Community Practice Connections™: Advances in Ovarian Cancer: Evolving Applications for PARP Inhibitors, Immunotherapy & Beyond!Aug 30, 20201.5
Publication Bottom Border
Border Publication